Cutter Capital Management LP Invests $8.21 Million in Moderna, Inc. (NASDAQ:MRNA)

Cutter Capital Management LP acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 197,500 shares of the company's stock, valued at approximately $8,212,000. Moderna makes up approximately 3.4% of Cutter Capital Management LP's investment portfolio, making the stock its 15th largest position. Cutter Capital Management LP owned approximately 0.05% of Moderna at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB boosted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the period. Compass Planning Associates Inc acquired a new position in Moderna in the 4th quarter valued at $37,000. Crowley Wealth Management Inc. bought a new position in Moderna in the 4th quarter worth $41,000. Finally, Itau Unibanco Holding S.A. lifted its position in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 0.5 %

Shares of NASDAQ:MRNA traded down $0.13 during midday trading on Friday, hitting $24.25. The company had a trading volume of 7,118,541 shares, compared to its average volume of 7,591,726. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The firm has a fifty day simple moving average of $28.89 and a 200 day simple moving average of $36.46. The stock has a market cap of $9.38 billion, a price-to-earnings ratio of -2.61 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company's revenue was down 35.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.07) earnings per share. Equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRNA. UBS Group cut their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Morgan Stanley reduced their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Barclays cut their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Leerink Partners decreased their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.